DFFN - ディフュ―ジョン・ファ―マシュ―ティカルズ （Diffusion Pharmaceuticals Inc.）

… coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) … owned by institutional investors. Diffusion Pharmaceuticals Company Profile (Get Rating) Diffusion … '' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat …

NEW YORK, April 02, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Diffusion Pharmaceuticals Inc. (the “Company”) (NasdaqCM: DFFN) with EIP Pharma Inc. pursuant to which Diffusion shareholders will end up owning 22.75% of the total number of outstanding shares of the combined company, subject to adjustment. KSF is seeking to determine whether the merger and the process that

Diffusion Pharmaceuticals (DFFN) is merging with privately held EIP Pharma in an all-stock deal to focus on neuro diseases. Read more here

Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies

Diffusion Pharmaceuticals (DFFN) said it will undertake a strategic review to evaluate options which could include a sale of the company.As part of its ongoing efforts to…

H.C. Wainwright upgraded clinical-stage biotech Diffusion Pharma (DFFN) to Buy from Neutral on Tuesday, citing the company''s Q2 2022 update on its lead candidate Trans Sodium…

https://www.investing.com/news/pro/hc-wainwright-upgrades-diffusion-pharma-to-buy-432SI-2873513

Diffusion Pharmaceuticals press release (DFFN): Q2 GAAP EPS of -$2.06 misses by $0.02.As of June 30, 2022, Diffusion had $28.5M in cash, cash equivalents, and marketable…

• Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022 • Reported Positive Effects in TSC Altitude Trial • Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Securities • Expected Cash Runway into First Quarter of 2024

H.C. Wainwright upgraded clinical-stage biotech Diffusion Pharma (DFFN) to Buy from Neutral on Tuesday, citing the company''s Q2 2022 update on its lead candidate Trans Sodium…

https://www.investing.com/news/pro/hc-wainwright-upgrades-diffusion-pharma-to-buy-432SI-2873513

Diffusion Pharmaceuticals press release (DFFN): Q2 GAAP EPS of -$2.06 misses by $0.02.As of June 30, 2022, Diffusion had $28.5M in cash, cash equivalents, and marketable…

• Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022 • Reported Positive Effects in TSC Altitude Trial • Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Securities • Expected Cash Runway into First Quarter of 2024

CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., the Company’s President and Chief Executive Officer, will be presenting at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022.